Industries > Pharma > Global Next-Generation Antibody Therapies Market Forecast 2018-2028

Global Next-Generation Antibody Therapies Market Forecast 2018-2028

Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies

PUBLISHED: 26 September 2018
PAGES: 217
PRODUCT CODE: PHA0333
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0333 Categories: , Tags: , , ,

The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023. In 2017, the antibody-drug conjugates segment held 45% of the global next-generation antibody therapies market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 217-page report you will receive 141 charts– all unavailable elsewhere.

The 217-page report provides clear detailed insight into the next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Next-Generation Antibody Therapies Market from 2018-2028

• Forecast of the Global Next-Generation Antibody Therapies market by Submarket:
• Antibody Fragments & ALPs
• Antibody-Drug Conjugates
• Biosimilar Antibodies
• Bispecific Antibodies
• Engineered Antibodies

• Forecast of the Global Antibody Fragments & ALPs submarket by Product:
• Kalbitor
• Other Antibody Fragments

• Forecast of the Global Antibody-Drug Conjugates submarket by Product:
• Adcetris
• Kadcyla
• Mylotarg
• Other ADCs

• Forecast of the Global Biosimilar Antibodies submarket by Product:
• Infliximab
• Adalimumab
• Rituximab
• Bevacizumab
• Trastuzumab
• Other Biosimilar mAbs

• Forecast of the Global Bispecific Antibodies submarket by Product:
• Blincyto
• Hemlibra
• Other Bispecific Antibodies

• Forecast of the Global Engineered Antibodies submarket by Product:
• Gazyva/Gazyvaro
• Poteligeo
• Fasenra
• Other Engineered Antibodies

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
• LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

Global Next-Generation Antibody Therapies Market Forecast 2018-2028

• Our study discusses the selected leading companies that are the major players in the next-generation antibody therapies market:
• Amgen, Inc.
• GlaxoSmithKline (GSK)
• Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Roche
• Sanofi
• Seattle Genetics, Inc.
• Shire plc

• This report discusses SWOT & STEP analysis of the next-generation antibody therapies market as well as factors that drive and restrain this market. This report also discusses the opportunities that can be tapped in this market.

• This report also discusses selected at that are in the pipeline.

Visiongain’s study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Next-Generation Antibody Therapies Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Next-Generation Antibody Therapies Market Forecast 2018-2028


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category